aTYR PHARMA INC: insider trades · United States · SEC (Form 4)

About aTYR PHARMA INC

aTyr Pharma Inc. (ticker: ATYR) is a United States-based clinical-stage biotechnology company listed on the Nasdaq market within the NYSE/NASDAQ ecosystem, with its principal executive office in San Diego, California, United States. The company was incorporated in Delaware in September 2005 and was founded by Professors Paul Schimmel and Xiang-Lei Yang, both renowned aminoacyl-tRNA synthetase scientists from The Scripps Research Institute. Its origin story is important for investors: aTyr is built on a distinctive scientific platform rather than on an established commercial franchise, which gives it long-term upside potential but also makes it highly dependent on clinical data and regulatory milestones. aTyr’s core business is the discovery and development of first-in-class medicines derived from its proprietary tRNA synthetase biology platform. The company describes its research as leveraging evolutionary intelligence to translate tRNA synthetase biology into therapies for fibrosis and inflammation. In practical terms, aTyr is a platform biotech: it seeks to convert a deep, differentiated scientific foundation into a pipeline of therapeutic candidates targeting high unmet medical need areas. Its lead asset is efzofitimod, a biologic candidate being developed for pulmonary sarcoidosis, a major form of interstitial lung disease. The company is also advancing additional programs, including ATYR0101, which expand the platform’s reach into other fibro-inflammatory disease settings. From a competitive standpoint, aTyr occupies a niche position in a crowded biotechnology landscape. It does not compete on scale with large-cap pharmaceutical companies; instead, its investment case rests on the novelty of its biology, the strength of its intellectual property estate, and the clinical validation of its lead program. This is a classic high-risk, high-reward profile typical of single-platform biotech names. aTyr’s geographic footprint is concentrated in the United States, with activities centered in San Diego, and it currently has no meaningful commercial sales infrastructure, consistent with its development-stage profile. Recent corporate highlights have focused on efzofitimod and its path forward. In 2025, the company reported top-line Phase 3 EFZO-FIT results in pulmonary sarcoidosis. In February 2026, aTyr announced that the FDA had accepted a Type C meeting request to discuss the program, with the meeting scheduled for mid-April 2026. In March 2026, the company provided its year-end 2025 results and corporate update, and more recently it disclosed a March 31, 2026 cash position of approximately $68.3 million in an SEC filing. For investors, ATYR remains a catalyst-driven Nasdaq biotech story whose valuation is likely to be shaped by clinical readouts, FDA feedback, financing needs, and execution on its fibrotic lung disease pipeline.